Zopiclone

1. 2026-10-19issueIssued info_card
2. 2026-09-07srcZopiclone as a Potent Positive Control for Assessing the Residual Effects of Hypnotic Drugs on Next Day Driving Performance: A Systematic Review
3. 2026-09-07srcAssociation of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death
4. 2026-09-07srcThe Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs
5. 2026-09-07srcThe Clinical and Forensic Toxicology of Z-drugs
6. 2026-09-07srcIn the Zzz zone: the effects of Z-drugs on human performance and driving
7. 2026-09-07srcZopiclone to treat insomnia in older adults: A systematic review
8. 2026-09-07srcAn accidental poisoning with mitragynine
9. 2026-09-07srcEfficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis
10. 2026-09-07srcComparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis
11. 2026-09-07srcStructural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABAA) receptor are different
12. 2026-09-07srcThe efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer's disease: a randomized, triple-blind, placebo-controlled trial
13. 2026-09-07srcAn Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions
14. 2026-09-07srcPharmacobezoar-Related Fatalities: A Case Report and Review.
15. 2026-09-07srcCase report of acute liver injury caused by the eszopiclone in a patient with chronic liver disease
16. 2026-09-07srcBenzodiazepine harm: how can it be reduced?
17. 2026-09-07srcThe European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023
18. 2026-09-07srcSedative hypnotics in older people with insomnia: meta-analysis of risks and benefits
19. 2026-09-07srcHypnotic drug risks of mortality, infection, depression, and cancer: but lack of benefit
20. 2026-09-07srcComparative study of effectiveness of cognitive-behavior therapy and zopiclone for chronic insomnia
21. 2026-09-07srcA comparison of complex sleep behaviors with two short-acting Z-hypnosedative drugs in nonpsychotic patients
22. 2026-09-07srcZopiclone: Is there cause for concern in addiction services and general practice?
23. 2026-09-07srcNon-benzodiazepine hypnotic use for sleep disturbance in people aged over 55 years living with dementia: a series of cohort studies
24. 2026-09-07srcDependence on zopiclone: a case report
25. 2026-09-07srcRisk predictors for hypnosedative-related complex sleep behaviors: a retrospective, cross-sectional pilot study
26. 2026-09-07srcClinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.
27. 2026-09-07srcNext-day effects of ramelteon (8 mg), zopiclone (7.5 mg), and placebo on highway driving performance, memory functioning, psychomotor performance, and mood in healthy adult subjects
28. 2026-09-07srcEszopiclone versus zopiclone in the treatment of insomnia
29. 2026-09-07srcMetabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zopiclone, and zolpidem
30. 2026-09-07srcPharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.
31. 2026-09-07srcMolecular actions of (S)-desmethylzopiclone (SEP-174559), an anxiolytic metabolite of zopiclone
32. 2026-09-07srcPharmacodynamic profile of Zaleplon, a new non-benzodiazepine hypnotic agent
33. 2026-09-07srcNew drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon
34. 2026-09-07srcClinically important drug interactions with zopiclone, zolpidem and zaleplon
35. 2026-09-07srcSchedules of controlled substances: placement of Zopiclone into Schedule IV. Final rule
36. 2026-09-07srcZopiclone: is it a pharmacologic agent for abuse?
37. 2026-09-07srcEszopiclone: its use in the treatment of insomnia
38. 2026-09-07srcActions and interactions of hypnotics on human performance: single doses of zopiclone, triazolam and alcohol
39. 2026-09-07srcZopiclone, the third generation hypnotic: a clinical overview
40. 2026-09-07srcZopiclone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy as an hypnotic
41. 2026-09-07srcA sleep laboratory evaluation of the long-term efficacy of zopiclone
42. 2026-09-07srcCritical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency
43. 2026-09-07srcPharmacokinetics and metabolism of zopiclone
44. 2026-09-07srcPharmacokinetic and clinical parameters of zopiclone and trimipramine when administered simultaneously to volunteers
45. 2026-09-07srcPharmacokinetics and metabolism of zopiclone
46. 2026-09-07srcClinical pharmacokinetics of zopiclone
47. 2026-09-07src[The effect of Imovane on sleep structure and respiratory indices during sleep in insomnia patients]
48. 2026-09-04issueIssued emergency
49. 2026-09-04issueIssued info_card
50. 2026-09-04issueIssued notice
51. 2026-07-03proposaldependence · taper
52. 2026-06-04proposal27 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
53. 2026-06-04publicationPublication — backfill
54. 2026-05-09revisionRevision 1
55. 2026-05-09absenceSearched PubMed/OpenAlex/WebSearch for "Cross-reference seed data against published sources" — no results
56. 2026-05-09genGeneration — pipeline-v5 · with 3 morepipeline-v5
57. 2026-05-09rungeneration run

The same entries, as forms: six forms.